Skip to main content
. 2021 May 14;12:590201. doi: 10.3389/fphar.2021.590201

FIGURE 1.

FIGURE 1

The structure and various polypharmacological properties and therapeutic potential of BCP. TNF-α, tumor necrosis factor alpha; IL, interleukin; PGE-2, prostaglandin E2; NO, nitric oxide; CINC-1, cytokine-induced neutrophil chemoattractant 1; NF-κB, nuclear factor kappa B; IFN-γ, interferon gamma; COX-2, cyclooxygenase-2; VCAM, vascular cell adhesion protein; iNOS, inducible nitric oxide synthase; GPx, glutathione peroxidase; SOD, superoxide dismutase; PPAR-γ, peroxisome proliferator-activated receptor gamma; PGC1-α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Nrf2, nuclear factor erythroid 2–related factor 2; FAS, fatty acid synthase; ATGL, adipose triglyceride lipase; ROS, reactive oxygen species; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; ART1, arginine ADP-ribosyltransferase 1; NFTs, neurofibrillary tangles; Aβ, amyloid beta; CB2R, cannabinoid receptor type 2.